BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 29274299)

  • 1. Anti-proliferative effect of rosiglitazone in the human T-lymphocyte leukaemia cell line Jurkat cells.
    Wei R; Yu F; Yang J; Gao H; Wang H; Hong T
    Cell Biol Int; 2018 May; 42(5):515-524. PubMed ID: 29274299
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of peroxisome proliferator-activated receptor gamma inhibits cell growth via apoptosis and arrest of the cell cycle in human colorectal cancer.
    Lin MS; Chen WC; Bai X; Wang YD
    J Dig Dis; 2007 May; 8(2):82-8. PubMed ID: 17532820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thiazolidinediones up-regulate insulin-like growth factor-1 receptor via a peroxisome proliferator-activated receptor gamma-independent pathway.
    Higashi Y; Holder K; Delafontaine P
    J Biol Chem; 2010 Nov; 285(47):36361-8. PubMed ID: 20843793
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pioglitazone induces cell growth arrest and activates mitochondrial apoptosis in human uterine leiomyosarcoma cells by a peroxisome proliferator-activated receptor γ-independent mechanism.
    Lützen U; Zhao Y; Lucht K; Zuhayra M; Marx M; Cascorbi I; Culman J
    Naunyn Schmiedebergs Arch Pharmacol; 2017 Jan; 390(1):37-48. PubMed ID: 27664035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rosiglitazone inhibits insulin-like growth factor‑1-induced polycystic kidney disease cell growth and p70S6 kinase activation.
    Liu C; Zhang Y; Yuan L; Fu L; Mei C
    Mol Med Rep; 2013 Sep; 8(3):861-4. PubMed ID: 23864113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rosiglitazone increases PPARgamma in renal tubular epithelial cells and protects against damage by hydrogen peroxide.
    Sommer M; Wolf G
    Am J Nephrol; 2007; 27(4):425-34. PubMed ID: 17622750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combined effect of honokiol and rosiglitazone on cell growth inhibition through enhanced G0/G1 phase arrest in hepatoma cells.
    Chen HC; Hsu HT; Weng JW; Chang YF; Hsia CY; Lee HC; Chi CW
    J Chin Med Assoc; 2016 Aug; 79(8):415-21. PubMed ID: 27094504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rosiglitazone attenuates insulin-like growth factor 1 receptor survival signaling in PC-3 cells.
    Papageorgiou E; Pitulis N; Manoussakis M; Lembessis P; Koutsilieris M
    Mol Med; 2008; 14(7-8):403-11. PubMed ID: 18475308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The PPARgamma ligands PGJ2 and rosiglitazone show a differential ability to inhibit proliferation and to induce apoptosis and differentiation of human glioblastoma cell lines.
    Morosetti R; Servidei T; Mirabella M; Rutella S; Mangiola A; Maira G; Mastrangelo R; Koeffler HP
    Int J Oncol; 2004 Aug; 25(2):493-502. PubMed ID: 15254749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rosiglitazone inhibits cell proliferation by inducing G1 cell cycle arrest and apoptosis in ADPKD cyst-lining epithelia cells.
    Liu Y; Dai B; Fu L; Jia J; Mei C
    Basic Clin Pharmacol Toxicol; 2010 Jun; 106(6):523-30. PubMed ID: 20210794
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thiazolidinediones regulate expression of cell cycle proteins in human prostate cancer cells via PPARgamma-dependent and PPARgamma-independent pathways.
    Lyles BE; Akinyeke TO; Moss PE; Stewart LV
    Cell Cycle; 2009 Jan; 8(2):268-77. PubMed ID: 19164938
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Repression of integrin-linked kinase by antidiabetes drugs through cross-talk of PPARγ- and AMPKα-dependent signaling: role of AP-2α and Sp1.
    Hahn SS; Tang Q; Zheng F; Zhao S; Wu J; Chen J
    Cell Signal; 2014 Mar; 26(3):639-47. PubMed ID: 24361375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor gamma ligands induce cell cycle arrest and apoptosis in human renal carcinoma cell lines.
    Yang FG; Zhang ZW; Xin DQ; Shi CJ; Wu JP; Guo YL; Guan YF
    Acta Pharmacol Sin; 2005 Jun; 26(6):753-61. PubMed ID: 15916743
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of lymphoma cell proliferation by peroxisomal proliferator-activated receptor-γ ligands via Wnt signaling pathway.
    Liu JJ; Dai XJ; Xu Y; Liu PQ; Zhang Y; Liu XD; Fang ZG; Lin DJ; Xiao RZ; Huang RW; Huang HQ
    Cell Biochem Biophys; 2012 Jan; 62(1):19-27. PubMed ID: 21837368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of G1 phase arrest and apoptosis in MDA-MB-231 breast cancer cells by troglitazone, a synthetic peroxisome proliferator-activated receptor gamma (PPARgamma) ligand.
    Yu HN; Lee YR; Noh EM; Lee KS; Kim JS; Song EK; Han MK; Lee YC; Kwon KB; Lee SJ; Youn HJ; Jung SH
    Cell Biol Int; 2008 Aug; 32(8):906-12. PubMed ID: 18474441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activation of peroxisome proliferator-activated receptor-γ (PPARγ) inhibits hepatoma cell growth via downregulation of SEPT2 expression.
    Cao LQ; Shao ZL; Liang HH; Zhang DW; Yang XW; Jiang XF; Xue P
    Cancer Lett; 2015 Apr; 359(1):127-35. PubMed ID: 25592041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proliferation and apoptosis effect of rosiglitazone on human ovarian cancer cell line SKOV3].
    Ren QC; Peng ZL; Tan X
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Mar; 40(2):217-22. PubMed ID: 19462893
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Troglitazone inhibits cell growth and induces apoptosis of B-cell acute lymphoblastic leukemia cells with t(14;18).
    Takenokuchi M; Saigo K; Nakamachi Y; Kawano S; Hashimoto M; Fujioka T; Koizumi T; Tatsumi E; Kumagai S
    Acta Haematol; 2006; 116(1):30-40. PubMed ID: 16809887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPARγ-dependent pathway in the growth-inhibitory effects of K562 cells by carotenoids in combination with rosiglitazone.
    Zhao H; Gu H; Zhang H; Li JH; Zhao WE
    Biochim Biophys Acta; 2014 Jan; 1840(1):545-55. PubMed ID: 24036327
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insights on distinct pathways of thiazolidinediones (PPARgamma ligand)-promoted apoptosis in TRAIL-sensitive or -resistant malignant urothelial cells.
    Plissonnier ML; Fauconnet S; Bittard H; Lascombe I
    Int J Cancer; 2010 Oct; 127(8):1769-84. PubMed ID: 20099277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.